- Home
- DRMA vs VMAR Comparison
DRMA vs VMAR Comparison
Compare DRMA & VMAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- VMAR
- Stock Information
- Founded
- DRMA 2014
- VMAR 1995
- Country
- DRMA United States
- VMAR Canada
- Employees
- DRMA N/A
- VMAR N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- VMAR Marine Transportation
- Sector
- DRMA Health Care
- VMAR Industrials
- Exchange
- DRMA Nasdaq
- VMAR Nasdaq
- Market Cap
- DRMA 4.5M
- VMAR 5.1M
- IPO Year
- DRMA 2021
- VMAR 2020
- Fundamental
- Price
- DRMA $6.45
- VMAR $5.36
- Analyst Decision
- DRMA Strong Buy
- VMAR Strong Buy
- Analyst Count
- DRMA 1
- VMAR 1
- Target Price
- DRMA $3.00
- VMAR $2,700.00
- AVG Volume (30 Days)
- DRMA 23.7K
- VMAR 29.6K
- Earning Date
- DRMA 08-11-2025
- VMAR 07-11-2025
- Dividend Yield
- DRMA N/A
- VMAR N/A
- EPS Growth
- DRMA N/A
- VMAR N/A
- EPS
- DRMA N/A
- VMAR N/A
- Revenue
- DRMA N/A
- VMAR $1,128,568.00
- Revenue This Year
- DRMA N/A
- VMAR N/A
- Revenue Next Year
- DRMA N/A
- VMAR $264.29
- P/E Ratio
- DRMA N/A
- VMAR N/A
- Revenue Growth
- DRMA N/A
- VMAR N/A
- 52 Week Low
- DRMA $5.74
- VMAR $4.04
- 52 Week High
- DRMA $37.90
- VMAR $675.00
- Technical
- Relative Strength Index (RSI)
- DRMA 43.91
- VMAR 32.07
- Support Level
- DRMA $5.94
- VMAR $5.50
- Resistance Level
- DRMA $7.33
- VMAR $6.28
- Average True Range (ATR)
- DRMA 0.63
- VMAR 0.35
- MACD
- DRMA -0.05
- VMAR -0.06
- Stochastic Oscillator
- DRMA 27.68
- VMAR 18.79
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About VMAR Vision Marine Technologies Inc.
Vision Marine Technologies Inc is in the business of designing and manufacturing electric outboard powertrain systems, power boats, and related technology and the renting of electric boats. The different models of the powerboats and electric boats manufactured by the company include Bruce 22, Fantail 217, Volt 180, and others. The company operates in two reportable business segments; Sale of electric boats and Rental of electric boats. The majority of the revenue for the company is generated from the Sale of electric boats segment. Geographically, the company generates revenue from its business in Canada, USA and other countries. A substantial portion of the overall revenue is generated from its business in USA.